Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 30, 2015 3:15 PM ET

Life Sciences Tools and Services

Company Overview of Sanford-Burnham Medical Research Institute

Company Overview

Sanford-Burnham Medical Research Institute, a laboratory-based life sciences research company, conducts collaborative research to find cures for human disease. It discovers the fundamental molecular causes of disease and devises the therapies of tomorrow; studies normal cellular processes and what causes them to go awry; uncovers the molecular basis of various rare inherited genetic diseases; engages in stem cell research and drug discovery; and studies type 1 diabetes, or cardiac and skeletal muscle disorders. The company was formerly known as Burnham Institute for Medical Research and changed its name to Sanford-Burnham Medical Research Institute in February 2010. Sanford-Burnham Medical R...

10901 North Torrey Pines Road

La Jolla, CA 92037

United States

Founded in 1976

Phone:

858-646-3100

Fax:

858-646-3199

Key Executives for Sanford-Burnham Medical Research Institute

Chief Executive Officer
President and Trustee
Age: 47
Chief Financial Officer, Chief Administrative Officer, Executive Vice President and Treasurer
Associate Director of Scientific Communications
Compensation as of Fiscal Year 2015.

Sanford-Burnham Medical Research Institute Key Developments

Eli Lilly and Sanford-Burnham Collaborate to Develop Immunological Therapies

Eli Lilly and Company and Sanford-Burnham Medical Research Institute have announced new research collaboration to discover and develop immunological therapies. Lilly and Sanford-Burnham will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjogren's Syndrome, inflammatory bowel disease and other autoimmune disorders. The comprehensive research collaboration is driven by Lilly's biotechnology capabilities and expertise in immunology, and Sanford-Burnham's deep expertise in understanding the fundamental cellular pathways regulating the immune system focusing on the immune checkpoint networks.

Sanford-Burnham Partners with Takeda on Novel Treatment for Cardiovascular Disease

Sanford-Burnham Medical Research Institute at Lake Nona (Sanford-Burnham) announced it has signed a two-year partnership agreement with Takeda Pharmaceutical Company Ltd. to study the potential role of several gene regulatory proteins as targets for the treatment of heart failure. Based on research conducted in Sanford-Burnham laboratories, the collaborating scientists will screen and develop molecules that have the potential to improve the metabolism and function of the failing heart. This is the third research collaboration between Takeda and Sanford-Burnham over five years. As a hallmark of previously successful projects, Takeda scientists will work side by side with researchers in Sanford-Burnham's laboratories. Additionally, the collaborators will work with colleagues in Sanford-Burnham's Conrad Prebys Center for Chemical Genomics to screen the Institute's vast library of compounds to find an effective molecule that can reactivate metabolism in heart failure patients, ultimately improving the outcome over currently available treatments.

Eli Lilly Collaborate with Sanford-Burnham Medical Research Institute to Investigate Immunological Therapies

Eli Lilly and Company and Sanford-Burnham Medical Research Institute announced that they will collaborate to discover and develop immunological therapies. Lilly and Sanford-Burnham will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjogren's Syndrome, inflammatory bowel disease and other autoimmune disorders. The comprehensive research collaboration will utilise Lilly's biotechnology capabilities and expertise in immunology, and Sanford-Burnham's expertise in understanding the fundamental cellular pathways regulating the immune system focusing on the immune checkpoint networks. This high degree of interaction is intended to allow the organizations to flexibly and efficiently advance projects to clinical investigation.

Similar Private Companies By Industry

Company Name Region
Gentris LLC United States
Clinical Assistance Programs, LLC United States
Horizon CombinatoRx Incorporated United States
iClinical Inc. United States
Cotter Brothers Corporation LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sanford-Burnham Medical Research Institute, please visit www.sanfordburnham.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.